Partner 14: Pronexus Analytical AB, Bromma, Sweden
Pronexus Analytical AB was founded as a spin-off company in 2003 by Prof. Kjell Fuxe, Prof. Urban Ungerstedt and Dr. Jan Kehr affiliated at the Department of Neuroscience and Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm. Pronexus is a privately owned fully proprietary and independent preclinical contract research organization (CRO) offering advanced services and collaborative projects focused on pharmacology and neurochemistry in experimental models of CNS and inflammatory diseases. Pronexus possesses world leading expertise and know-how in minimally invasive techniques for neurochemical monitoring in vivo, including microdialysis and voltammetric biosensors. The analytical services include chromatographic techniques and immunoassays for determination of surrogate markers of disease states, including neurotransmitters, metabolites, inflammatory molecules and other proteins in microdialysates, tissue extracts and body fluids. Pronexus research laboratories with full regulatory approvals include the central bioanalytical laboratory and the animal research facility.
Partner 14 team leader:
Dr Jan Kehr
Pronexus will analyse neurotransmitters and metabolites in humanised mice in WP5. The main focus will be put on evaluation of possible effects on levels of monoamine neurotransmitters serotonin, noradrenaline and dopamine in brain structures relevant to diseases associated to the various humanised mouse models. In addition, molecular markers of tissue energy state and metabolism such as glucose, lactate, pyruvate, physiological amino acids and purines will be monitored by microdialysis in mouse liver at different time points.
During the last 25 years, Dr. Kehr carried-out several larger academic research projects focused on neuropharmacology of major neurotransmitter systems and related neurochemical techniques allowing in vivo monitoring of neurotransmitters and other biomarkers in animal models of CNS disorders. Being in positions of a project leader, product manager, senior scientist and a group leader, Dr. Kehr learned to act as a principal investigator, or as a collaboration partner in the projects at the national, as well as international levels. As a CEO of Pronexus, Dr. Kehr acquired a broad experience and built up a solid competence in providing advanced services to pharmaceutical industry with projects related to in vivo lead optimization and proof-of-concept studies in late phase of drug discovery. Through his affiliation at Karolinska Institutet, Dr. Kehr was a study director for a postgraduate program Nanobiology and biological physics and a study director for undergraduate course in Pharmacology and Toxicology for the biomedicine program at KI. Dr. Kehr was a main supervisor of two PhD students and one licentiate candidate, co-supervisor of three PhD students and supervisor for two master science (MS) students from Royal Institute of Technology, Stockholm.
1. Kehr J, et al. (2011). Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats. Br J Pharmacol, 164, 1949-1958.
2. Hascup KN, et al. (2011). Resting Glutamate Levels and Rapid Glutamate Transients in the Prefrontal Cortex of the Flinders Sensitive Line Rat-A Genetic Rodent Model of Depression. Neuropsychopharmacology,36,1769
3. Weikop P, et al. (2007). Differential effects of adjunctive methylphenidate and citalopram on extracellular levels of serotonin, noradrenaline and dopamine in the rat brain. Eur Neuropsychopharmacol, 17, 658-671.
4. Ogren SO, et al. (2006). Galanin receptor antagonists. A potential novel pharmacological treatment for mood disorders. CNS Drugs, 20, 633-654.
5. Yoshitake T, et al. (2004). Enhanced hippocampal noradrenaline and serotonin release in galanin-overexpressing mice following repeated forced swimming test. Proc Natl Acad Sci USA, 101, 354-359.